{"prompt": "['1.0', 'OBJECTIVES', '1.1', 'Primary Objective', 'To evaluate the longitudinal quality of life of participants with HIV-associated KS during', 'treatment with bleomycin and vincristine at a single institution in East Africa.', '1.2', 'Secondary Objective', 'To explore baseline and time-dependent correlates of improvements in quality of life', '(QOL).', '1.3', 'Exploratory Objective', 'To assess quality control (completeness and accuracy) in data capture of adverse events,', 'clinical benefit, and objective response for site evaluation and training purposes.', 'AMC-S007 (Version 2.0) 20MAR2018', '11', 'NCI Version Date 20MAR2018']['2.0', 'BACKGROUND', '2.1', 'Study Disease', 'Kaposi sarcoma (KS) is a vascular inflammatory tumor of endothelial origin caused by', 'Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8', '(HHV-8). 1 HIV infection and immunosuppression dramatically increase the risk of KS', 'among people infected with KSHV.', 'KS is the most common malignancy seen in patients with human immunodeficiency virus', 'infection. The incidence of HIV associated KS remains high in parts of Africa where rates', 'of both HIV and HHV-8 infection are high, but treatment options are often limited. In high', 'resource countries, treatment for advanced AIDS-associated KS, in addition to', 'antiretroviral treatment, typically includes chemotherapy. 2-8 While chemotherapy has been', 'shown to reduce the burden of disease, it has not been shown to alter survival outcomes.', 'The goal of treatment is palliation and improvement in quality of life (QOL). However, in', 'low resource countries, such as Tanzania, the optimal treatment and the effect of treatment', 'on quality of life is unknown.', '2.2', 'Treatment Regimen', '2.2.1 Bleomycin and vincristine', 'This study will only use standard of care drugs for the treatment of KS. The', 'selection of bleomycin and vincristine sulfate (BV), and its choice over another', 'regimen available in Tanzania, adriamycin, bleomycin, and vincristine (ABV), was', 'based on several considerations. First, the large, randomized, controlled trials of', 'liposomal anthracyclines versus BV or ABV were all conducted pre-highly active', 'antiretroviral therapy (HAART). For example, in the randomized trial that', 'compared pegylated liposomal doxorubicin (PLD) and BV reported by Stewart et', 'al., only half of the patients in each arm of the study were receiving any', 'antiretroviral therapy (ART), and ART was confined to single or combination', 'nucleoside reverse transcriptase inhibitors (NRTIs.\u00b2', 'In studies that have used rigorous response criteria, there was no evidence that BV', 'was inferior to ABV with respect to objective, strictly defined response rates.2-4 On', 'the other hand, there was good evidence that BV had a superior toxicity profile', 'compared to ABV, which was associated with a higher rate of hematologic toxicity', 'and treatment delays for neutropenia and infection and also presents the risk of', 'serious cardiotoxicity. In addition, as noted by Stewart et al.,\u00b2 BV was also', 'associated with considerably less myelosuppression than PLD, which may be', 'particularly important in locales where hematopoietic growth factors like', 'granulocyte-colony stimulating factor (G-CSF) are not available and where access', 'to blood component transfusion is limited.', '2.3', 'Study Design and Rationale', 'HIV seroprevalence among Tanzanians age 15-49 is estimated at 5.1%,9 resulting in', 'approximately 2.2 million HIV-positive persons within the country. Little is known about', 'either the rate of objective response of KS to standard chemotherapy in this setting or its', 'influence on QOL. Bugando Medical Centre (BMC) is a provisional AMC site and the', 'current proposal is exploratory and intended to develop clinical research and database', 'AMC-S007 (Version 2.0) 20MAR2018', '12', 'NCI Version Date 20MAR2018']['management capacity. Additionally, knowledge of both the objective response rate to the', 'current standard therapy and its influence on QOL, using a standardized questionnaire', 'validated in Swahili, would be useful before embarking on clinical trials of other treatments', 'for KS conducted with the AMC.', 'This is a prospective observational study to evaluate the quality of life of participants', 'receiving BV for HIV-associated KS at a single institution in Tanzania. All participants', 'presenting for care of HIV-associated KS at BMC during a 1-year study period will be', 'approached for enrollment.', 'At enrollment, KS stage, clinical symptoms, CD4 count, complete blood count (CBC),', 'liver, and renal function labs, and history of opportunistic infection will be recorded. The', 'extent of KS will be evaluated at baseline and after each cycle of treatment, and response', 'assessed using standard AMC criteria. The Functional Assessment of Cancer Therapy-', 'General (FACT-G) QOL questionnaire has been used successfully in HIV-associated', 'clinical trials to collect data in 4 categories: physical, emotional, functional, and social', 'wellbeing. A Swahili version has been validated and will be used in the current proposal. 5', 'This questionnaire will be completed at four time points: prior to initiating treatment, after', '3 cycles, at the end of therapy, and 3 months off therapy.', 'Participants will receive institutional standard of care treatment with BV, administered on', 'day one of each 21-day chemotherapy cycle. Vincristine sulfate will be administered at a', 'dose of 2 mg (fixed dose) over 1 minute into the sidearm of a rapidly flowing intravenous', 'infusion every 3 weeks. The vincristine infusion will be followed by bleomycin', 'administered at a dose of 15 units/m\u00b2 over 10 minutes every 3 weeks.', 'Treatment with BV will continue for six cycles or until toxicity requiring discontinuation', 'of chemotherapy, or the local physician determines that alternative therapy is required,', 'whichever occurs first.', 'Institutional standard pre-treatment staging evaluation includes chest X-ray and physical', 'history and exam. Complete blood cell counts, and serum liver/ renal function analysis will', 'be required at each pretreatment visit. Other clinical or laboratory evaluations will be', 'performed as deemed necessary by the medical provider. Clinical benefit, objective tumor', 'response, and toxicity will be assessed every 3 weeks, prior to initiating each new', 'chemotherapy cycle.', 'AMC-S007 (Version 2.0) 20MAR2018', '13', 'NCI Version Date 20MAR2018']['3.0', 'PARTICIPANT SELECTION', 'A CTEP-registered investigator (Dr. Nestory Masalu or Dr. Kristin Schroeder) will', 'document that each protocol participant meets all stated eligibility criteria. Satisfaction of', 'eligibility requirement will be documented prior to participant enrollment. In compliance', 'with CTEP policy, no exceptions to eligibility criteria will be granted under any', 'circumstance.', 'NOTE: Institutions may use this section of the protocol as an eligibility checklist for source', 'documentation if it has been reviewed, signed, and dated before registration/randomizatior', 'by the study investigator. If used as source documentation, this checklist must be printed,', 'the investigator must check each item to document their assessment that the participant', 'meets each eligibility criterion, and the completed checklist must be maintained in the', \"participant's chart.\", 'Participant ID Number: S007-', \"Patient's Initials (L, F, M):\", '3.1', 'Eligibility Criteria', '3.1.1 HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or', 'chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry', 'and confirmed by a licensed Western blot or a second antibody test by a method', 'other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1', 'RNA viral load.', 'NOTE: The term \"licensed\" refers to a U.S. FDA-approved kit or for sites located', 'in countries other than the U.S., a kit that has been certified or licensed by an', 'oversight body within that country and validated internally.', 'World Health Organization (WHO) and Centers for Disease Control and Prevention', '(CDC) guidelines mandate that confirmation of the initial test result must use a test', 'that is different from the one used for the initial assessment. A reactive initial rapid', 'test should be confirmed by either another type of rapid assay or an E/CIA that is', 'based on a different antigen preparation and/or different test principle (e.g., indirect', 'versus competitive), or a Western blot or a plasma HIV-1 ribonucleic acid (RNA)', 'viral load.', '3.1.2', 'Participants must have pathologically confirmed Kaposi sarcoma.', '3.1.3 Participants should not have had prior therapy for their Kaposi sarcoma.', '3.1.4 All participants must be on stable antiretroviral therapy (ART) for a minimum of', '12 weeks prior to study entry with an acceptable regimen that adheres to national', 'guidelines for treatment of HIV infection.', '3.1.5 Age >18 years. Because no dosing or adverse event data are currently available on', 'the use of BV in participants <18 years of age, children are excluded from this', 'study.', '3.1.6 ECOG performance status 2 (Karnofsky performance status > 50%, see Appendix', 'II).', 'AMC-S007 (Version 2.0) 20MAR2018', '14', 'NCI Version Date 20MAR2018']", "completion": ""}